Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2019 08/16/2019 08/19/2019 08/20/2019 08/21/2019 Date
93.31(c) 94.74(c) 95.22(c) 95.26(c) 95.57 Last
2 385 612 2 675 096 1 983 230 2 425 641 1 219 241 Volume
+0.45% +1.53% +0.51% +0.04% +0.33% Change
More quotes
Financials (USD)
Sales 2019 17 283 M
EBIT 2019 10 140 M
Net income 2019 6 470 M
Debt 2019 1 302 M
Yield 2019 -
Sales 2020 19 124 M
EBIT 2020 11 133 M
Net income 2020 7 559 M
Finance 2020 5 310 M
Yield 2020 -
P/E ratio 2019 10,9x
P/E ratio 2020 9,15x
EV / Sales2019 3,98x
EV / Sales2020 3,25x
Capitalization 67 515 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants, for... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
08/19Who is next in big pharma's merger spree?
RE
08/19CELGENE CORPORATION : - U.S. FDA Approves INREBIC as First New Treatment in Near..
AQ
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16CELGENE : U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Near..
BU
07/30CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/30CELGENE : Second-Quarter Revenue at Celgene Surpasses Wall Street Targets
DJ
07/30CELGENE : 2Q Earnings Snapshot
AQ
07/30CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
07/30CELGENE : Reports Second Quarter 2019 Operating and Financial Results
BU
07/29Pfizer to spinoff, merge off-patent drugs unit with Mylan
RE
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Stock Trading Strategies
CELGENE CORPORATION - 03/28
In an accumulation phase
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
07:38aAstraZeneca Imfinzi combination fails advanced lung cancer study
RE
05:45aSlowing Share Buybacks Remove a Pillar of Stock Market
DJ
02:47aBayer Sells Pet-Health Unit for $7.6 Billion -- WSJ
DJ
02:27aASTRAZENECA : Imfinzi, Tremelimumab Combination Didn't Meet Primary Endpoint
DJ
08/20Health Care Lower as Litigation, Deal Risks Linger -- Health Care Roundup
DJ
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 100,14  $
Last Close Price 95,26  $
Spread / Highest target 26,0%
Spread / Average Target 5,13%
Spread / Lowest Target -11,8%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION48.63%67 515
JOHNSON & JOHNSON2.48%344 675
ROCHE HOLDING LTD.12.16%238 287
MERCK AND COMPANY12.09%219 296
NOVARTIS17.97%204 985
PFIZER-19.40%191 430